QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Related Article All Versions of this Article: mol.107.034926v1 71/5/1200    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Related articles in MolPharm Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neubig, R. R. Search for Related Content PubMed PubMed Citation Articles by Neubig, R. R.

Perspective

Missing Links: Mechanisms of Protean Agonism

Department of Pharmacology and Department of Internal Medicine (Cardiovascular Medicine), the University of Michigan Medical School, Ann Arbor, Michigan

The concept of pharmacological efficacy has been much discussed recently with significant interest both in inverse agonists and in protean agonists (i.e., compounds with functional selectivity for different effector responses). Although first proposed in the mid-1990s, the pharmacological and therapeutic importance of these concepts is now receiving wider support. Two articles in recent issues of Molecular Pharmacology, Lane et al. (p. 1349, current issue) and Galandrin and Bouvier (Mol Pharmacol 70:1575–1584, 2006), provide new mechanistic information on functionally selective ligands at the pharmacologically important D2 dopamine receptor and the ₁ and ₂ adrenergic receptors. Each article bridges a gap between recent biophysical studies showing distinct receptor conformations produced by different ligands and the increasing number of reports of discordant outputs by a single ligand to two effector readouts. The Lane et al. study clearly demonstrates G protein-specific actions of D₂ dopamine receptor ligands. These range from equivalent responses for G_o and G_i activation by norapomorphine and 7-hydroxy-2-dipropylaminotetralin to S-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine, which is an agonist for G_o activation and an inverse agonist at G_i1 and G_i2. Likewise, Galandrin and Bouvier describe a two-dimensional Cartesian efficacy approach in which propranolol is an agonist for extracellular signal-regulated kinase activation, probably through -arrestin, while functioning as an inverse agonist for adenylyl cyclase activation. Thus, these two important articles further solidify the concepts of functional selectivity and protean agonism and begin to define the first postreceptor step in actions of protean agonist ligands.

Address correspondence to: Dr. Richard R. Neubig, Department of Pharmacology, 1301 MSRB III, 1150 W. Medical Center Drive, University of Michigan Medical School, Ann Arbor, MI 48109-0632. E-mail: rneubig{at}umich.edu

Related articles in MolPharm:

Protean Agonism at the Dopamine D₂ Receptor: (S)-3-(3-Hydroxyphenyl)-N-propylpiperidine Is an Agonist for Activation of G_o1 but an Antagonist/Inverse Agonist for G_i1,G_i2, and G_i3

J. Robert Lane, Ben Powney, Alan Wise, Steven Rees, and Graeme Milligan
MolPharm 2007 71: 1349-1359. [Abstract] [Full Text]  

This article has been cited by other articles:

				R. Seifert and S. Dove Functional Selectivity of GPCR Ligand Stereoisomers: New Pharmacological Opportunities Mol. Pharmacol., January 1, 2009; 75(1): 13 - 18. [Abstract] [Full Text] [PDF]

				M. Sato, D. S. Hutchinson, B. A. Evans, and R. J. Summers Mol. Pharmacol., November 1, 2008; 74(5): 1417 - 1428. [Abstract] [Full Text] [PDF]

				M. T. Drake, J. D. Violin, E. J. Whalen, J. W. Wisler, S. K. Shenoy, and R. J. Lefkowitz {beta}-Arrestin-biased Agonism at the {beta}2-Adrenergic Receptor J. Biol. Chem., February 29, 2008; 283(9): 5669 - 5676. [Abstract] [Full Text] [PDF]